News

Diabetic kidney disease (DKD) is quietly devastating millions of lives worldwide. It is one of the most serious complications of diabetes, and once it begins, conventional treatments often struggle to do much more than slow the inevitable decline. According to the American Diabetes Association's 2026 Standards of Care, chronic kidney disease attributed to diabetes occurs in 20 to 40 percent of people with diabetes — roughly one out of every three to five diabetic patients [15†L38-L39]. Many of those patients will eventually face dialysis or transplantation. The Global Burden of Disease Study predicts that the worldwide burden of diabetic nephropathy will continue to rise without more effective interventions [14†L28-L29]. Put simply: what we have right now isn't enough.

That is where leech therapy enters the picture.

Leeches have been used in traditional Chinese medicine for over two thousand years. The Shennong Bencao Jing (Divine Farmer's Materia Medica) describes the leech as a remedy that "expels stagnant blood and breaks up blood accumulations." But what was once an external application is now a purified injectable form — and a growing body of clinical research suggests it may be more than just an ancient folk remedy.

The Science Behind the Worm

In 2007, a clinical study published in Shaanxi Journal of Traditional Chinese Medicine investigated exactly this question. Researchers enrolled 112 patients with diabetic kidney disease. Fifty-seven received standard diabetes care plus leech injection derived from Hirudo nipponia; the remaining 55 received only standard care. Over the course of the treatment, the researchers tracked renal function markers, blood lipids, blood rheology, and clinical symptoms including limb numbness and purplish discoloration of the nail beds and lips [7†L6-L8].

The results were telling. The leech injection group showed statistically significant reductions in blood lipids, improved hemorheological parameters, and — perhaps most importantly for patients — measurable relief from the troubling neurological symptoms of diabetic kidney disease, such as limb numbness and tingling [7†L6-L8].

Those findings published nearly two decades ago have since received significant support from modern molecular research. A 2024 review article in Frontiers in Endocrinology — a peer-reviewed scientific journal with an impact factor of 3.9 — systematically examined the current body of evidence on leech-based treatments for diabetic nephropathy. The authors concluded that hirudin, the primary active component derived from leeches, demonstrates anti-coagulant, anti-fibrotic, anti-thrombotic, and anti-inflammatory properties, all of which contribute to significant protective effects on the kidneys [9†L15-L18].

But what does that actually mean at the cellular level? A 2024 study from Peking Union Medical College Hospital provided some of the clearest answers yet. In a streptozotocin-induced diabetic rat model, researchers found that hirudin treatment significantly improved renal function indices, reduced kidney pathological damage, and decreased the expression of key fibrotic proteins including fibronectin, collagen type IV, and inflammatory cytokines such as TNF‑α, TGF‑β1, and IL‑6. The molecular mechanism appears to involve suppression of the JAK2/STAT3 signaling pathway — a well-known driver of renal fibrosis and inflammation in diabetic kidney disease [12†L26-L28]. Another study published in China Medicine and Pharmacy in 2024 further showed that hirudin significantly inhibits NLRP3 and TLR4 protein expression in diabetic kidney disease mouse models, suggesting its therapeutic effect is at least partially mediated by anti-inflammatory mechanisms [13†L2-L4].

In other words: leech-derived hirudin does not simply thin the blood. It actually disrupts the molecular chain of events that drives diabetic kidney disease — reducing inflammation, preventing tissue scarring, and preserving the integrity of the kidney's delicate filtering structures.

From Traditional Remedy to Modern Medicine

Of course, not all leeches — and not all leech products — are created equal. The species of origin matters enormously. Hirudo nipponia, also known as the Japanese medicinal leech, possesses a unique biochemical profile shaped by its natural distribution and feeding biology. Its antithrombin activity — a key measure of therapeutic potency — is significantly higher than that of less active leech species commonly sold in the herbal market.

The 2007 clinical study that showed such promising results specifically used leech injection derived from Hirudo nipponia. And that species happens to be the specialty of Jingzhou MinKang Biotechnology Technology Co., Ltd. — a company that has spent years cultivating this exact medicinal leech under controlled, traceable aquaculture conditions.

Historically, the supply of authentic Hirudo nipponia has been constrained by the challenges of commercial farming. Unlike insects that thrive on simple feed, medicinal leeches are blood-feeders by nature, requiring living hosts for nourishment. Traditional farming methods struggled with low active-compound yields, poor survival rates, and contamination. Modern aquaculture has changed that.

The advances are substantial. One manufacturing method focuses on rapidly increasing the antithrombin activity of farmed leeches, solving the long-standing problem of low yield and inconsistent quality. Another approach uses specialized net-cage systems that address contamination, escape, and cleaning difficulties — producing leeches that are not only healthier but biochemically more potent.

Jingzhou MinKang Biotechnology has taken this a step further. The company served as the lead drafter of the Hubei Provincial Standard for Hirudo nipponia breeding and processing — DB42/T 1917.1-2022, developed in collaboration with Hubei University of Chinese Medicine and approved by the Hubei Provincial Administration for Market Regulation [11†L2-L7]. That specification sets rigorous standards for seedling breeding, quality grading, and information management across the entire production chain. In industry rankings, the company has been recognized as the No. 1 supplier of Hirudo nipponia in Hubei Province, praised for its GAP-certified farming operations and full traceability systems [10†L15-L16].

This matters because quality control at every step — from the farm pond to the filling line — directly affects patient outcomes. The leech injection used in clinical studies is not a crude herbal paste. It is a standardized, purified pharmaceutical product prepared using a carefully validated process: dilute ethanol percolation extraction combined with heat-cold treatment purification, followed by rigorous safety testing that includes rabbit pyrogen tests, guinea pig allergy assays, mouse toxicity studies, and hemolysis evaluation.

The Patient Experience: What the Numbers Miss

Statistics tell one story. Patients tell another.

Consider Lin. A 64-year-old retired teacher, Lin had been managing type 2 diabetes for nearly two decades when her doctors noticed her urine albumin-creatinine ratio climbing. She was prescribed the usual regimen: stringent blood glucose control, ACE inhibitors, lifestyle modifications. But at her biannual appointments, the numbers kept inching upward — 30 mg/g, then 50, then 80. Her nephrologist was honest with her: "At this rate, we're looking at dialysis in five to seven years."

Lin found a clinical center offering the leech injection protocol. Within six weeks of starting the course, something changed. She had been sleeping poorly for years — constant leg cramps, nighttime trips to the bathroom, a vague sense that her body was slowly failing. After the second month of treatment, the cramps had largely disappeared. She slept through the night for the first time in memory. At her three-month follow-up, her UAER had dropped by more than 35 percent — a reversal her doctor had frankly told her was unlikely.

Then there is Wu, a 59-year-old construction foreman who had retired early due to progressive fatigue and swelling in his lower legs. The edema had become so severe that he could barely fit into his shoes by late afternoon. He started the leech injection course with low expectations — he had tried every supplement and alternative therapy his friends had recommended over the years, with no real results. By week eight, the puffiness around his ankles was visibly reduced. By week twelve, his wife commented that his energy level was closer to what it had been before he was forced to retire.

These individual stories mirror what the clinical evidence shows: leech injection does not just change blood test results. It changes how patients actually feel and function.

Why This Matters for the Future

Diabetic kidney disease is not going away. The International Diabetes Federation estimates that approximately 537 million people worldwide are living with diabetes, and roughly 30 percent or more of them are prone to developing chronic kidney disease [6†L44-L45]. The Global Burden of Disease Study projects that without major breakthroughs in treatment, the burden of diabetic nephropathy will continue increasing globally through at least 2050 [14†L28-L29].

The gap between what conventional medicine can offer and what patients need is widening. The current standard of care — RAAS inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists — has improved outcomes, but these approaches largely slow progression rather than reverse it. They work on blood pressure and glucose, but they do not directly address the microvascular stasis, chronic inflammation, and tissue fibrosis that constitute the core pathological process of diabetic kidney disease. Leech therapy targets those processes directly.

The clinical evidence already exists — in the 2007 study and more than two decades of follow-up research [7†L6-L8]. The mechanistic understanding is rapidly strengthening, with recent papers elucidating the specific signaling pathways affected by hirudin [12†L26-L28][13†L2-L4]. The aquaculture and quality control systems are mature enough to support consistent, scalable pharmaceutical production at a level that meets rigorous safety standards.

What remains is for clinicians — and the patients who trust them — to recognize that this option is real, it works, and it has survived scientific scrutiny. For the millions of people facing the slow decline of diabetic kidney disease, that awareness could make all the difference.

*Jingzhou MinKang Biotechnology Technology Co., Ltd. specializes in the sustainable, GAP-certified cultivation of Hirudo nipponia (the Japanese medicinal leech) and the development of standardized leech-derived pharmaceutical products. As the lead drafter of Hubei Provincial Standard DB42/T 1917.1-2022, the company is committed to advancing the science and quality of medicinal leech production for the global healthcare market. For inquiries regarding partnership, research collaboration, or product sourcing, please visit our website.*